Catalent, Inc. (NYSE:CTLT) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Catalent, Inc. (NYSE:CTLT) have been assigned an average recommendation of “Hold” from the thirteen research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $52.46.

A number of equities analysts recently commented on the company. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, February 20th. Barclays increased their price objective on Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. StockNews.com assumed coverage on Catalent in a report on Friday. They issued a “sell” rating on the stock. Stephens restated an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a report on Thursday, April 4th. Finally, UBS Group restated a “neutral” rating and issued a $63.50 price objective (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th.

Institutional Investors Weigh In On Catalent

Several hedge funds have recently modified their holdings of CTLT. Cetera Advisor Networks LLC boosted its position in shares of Catalent by 7.1% in the first quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock valued at $217,000 after acquiring an additional 130 shares during the period. Private Advisor Group LLC boosted its position in shares of Catalent by 18.0% in the first quarter. Private Advisor Group LLC now owns 2,957 shares of the company’s stock valued at $328,000 after acquiring an additional 452 shares during the period. Panagora Asset Management Inc. boosted its position in shares of Catalent by 125.8% in the first quarter. Panagora Asset Management Inc. now owns 12,979 shares of the company’s stock valued at $1,439,000 after acquiring an additional 7,231 shares during the period. Yousif Capital Management LLC boosted its position in shares of Catalent by 2.0% in the first quarter. Yousif Capital Management LLC now owns 24,561 shares of the company’s stock valued at $2,724,000 after acquiring an additional 470 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Catalent by 1.8% in the first quarter. Dimensional Fund Advisors LP now owns 991,019 shares of the company’s stock valued at $109,904,000 after acquiring an additional 17,813 shares during the period.

Catalent Price Performance

Shares of CTLT opened at $55.48 on Friday. The company has a market capitalization of $10.04 billion, a price-to-earnings ratio of -8.16, a P/E/G ratio of 6.02 and a beta of 1.20. Catalent has a fifty-two week low of $31.45 and a fifty-two week high of $60.20. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73. The business’s 50-day moving average is $56.81 and its 200-day moving average is $48.24.

Catalent (NYSE:CTLT) last issued its earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. Catalent’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.62 EPS. Equities research analysts expect that Catalent will post 0.28 EPS for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.